Trials / Completed
CompletedNCT02969109
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-muscle Invasive Bladder Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 417 (actual)
- Sponsor
- Genomic Health®, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
Conditions
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-09-18
- Completion
- 2018-09-18
- First posted
- 2016-11-21
- Last updated
- 2021-03-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02969109. Inclusion in this directory is not an endorsement.